Current Report Filing (8-k)
June 21 2017 - 4:12PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2017
Five Prime Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36070
|
|
26-0038620
|
|
(state or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
Two Corporate Drive
South San Francisco, California
|
|
94080
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (415)
365-5600
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicated by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On June 21, 2017, Five Prime Therapeutics, Inc. (the
“Company”) issued a press release announcing that Lewis T. Williams, M.D., Ph.D. plans to transition from his position as President, Chief Executive Officer and Chairman of the Board of Directors (the “Board”) to the
role of Executive Chairman of the Board in 2018. The Board will conduct a comprehensive search for a candidate to fill the position of Chief Executive Officer, and Dr. Williams will remain in his current position until the new Chief
Executive Officer has been appointed.
A copy of the press release is filed herewith as Exhibit 99.1 and the information contained therein is incorporated
by reference into this Current Report on Form
8-K.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release, dated June 21, 2017.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Five Prime Therapeutics, Inc.
|
|
By:
|
|
/s/ Francis Sarena
|
|
|
|
Francis Sarena
|
|
|
|
Chief Strategy Officer and Secretary
|
Dated: June 21, 2017
3
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release, dated June 21, 2017.
|
4
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
